GSK pulls plug on new biopharma facility
31 Jul 2017 by Evoluted New Media
GSK has shelved plans to build a new £350m facility in Cumbria as it announced new plans to improve its efficiency and competitiveness.
GSK has shelved plans to build a new £350m facility in Cumbria as it announced new plans to improve its efficiency and competitiveness.
More than £140m will be invested in other sites around the country for respiratory and HIV medicine, while GSK’s cephalosporin antibiotics business will be sold. The pharmaceutical giant will also be selling its Horlicks and MaxiNutrition brands in the UK.
Roger Connor, President at GSK Global Manufacturing and Supply, said: “We have a substantial manufacturing presence in the UK and continue to support the network with new investment of more than £140million in the next 3 years. At the same time, we have had to make some decisions which we know will cause uncertainty for some of our employees. We will do all we can to support them through this process.”
The facility in Ulverston would have seen hundreds of jobs created during construction as well as 500 permanent jobs. It would have been the first GSK manufacturing facility built in the UK for almost 40 years. The investments made by GSK will be in Ware, Hertfordshire, Barnard Castle, County Durham and Montrose.
